Elixinol Wellness lifted Q3 gross profit 27% and delivered a fourth consecutive quarter of positive underlying operating cash flow, despite statutory operating cash flow remaining negative and cash below A$1 million. The proposed all-scrip Vitable acquisition could add scale, but shareholder approval and a thin liquidity buffer remain important next tests.
- Q3 sales revenue rose 6% to A$3.6 million
- Gross profit increased 27% to A$1.5 million
- Gross margin expanded to 42% from 35%
- Underlying operating cash flow was positive for the fourth consecutive quarter
- Vitable acquisition remains subject to shareholder approval
Gross Profit Outpaces Revenue Growth
Elixinol Wellness Ltd (ASX:EXL) is making more from each dollar of sales, even as the top line grows modestly. Q3 FY26 sales revenue rose 6% to A$3.6 million, while gross profit jumped 27% to A$1.5 million and gross margin widened to 42%, up from 35% a year earlier.
The improvement came alongside a 26% reduction in operating expenses. Employee costs fell 13%, marketing expenditure declined 21% and administration and corporate costs were down 28%, according to the quarterly report. For the first nine months of FY26, revenue increased 6% and gross profit rose 34% on the prior corresponding period.
The Healthy Chef contributed A$0.87 million of quarterly revenue, up 13%, with gross profit rising 10% to A$0.52 million at a 60% margin. The brand continued its Stage One rollout through Priceline Pharmacy, while Mt Elephant began placing Cake Pods in more than 700 Coles supermarkets. Australian Primary Hemp ingredients revenue increased 81% at an improved margin.
Underlying Cash Flow Improves, But Liquidity Remains Tight
Elixinol reported underlying operating cash flow of A$0.04 million for the quarter, its fourth consecutive positive result. That measure excludes financing costs, income taxes, timing adjustments and non-recurring items, so it is not the same as the Appendix 4C operating cash flow figure.
On the statutory measure, operating cash flow was a negative A$0.323 million. The company said the quarter included prior-period and out-of-cycle payments, interest paid to secured loan note holders and costs associated with the US divestment. Cash receipts from customers were A$3.935 million, ahead of quarterly sales because of collections from receivables carried over from the previous quarter.
Cash on hand fell to A$0.927 million at 30 September, with only A$79,000 of unused finance facilities available. The Appendix 4C calculated estimated funding of 3.1 quarters using statutory quarterly operating cash outflow, while the group’s financing facilities included trade debtor finance, e-commerce revenue advances and secured debt. That leaves the quality and repeatability of the underlying cash improvement as a more consequential measure than the headline quarterly result alone.
Vitable Deal Adds Scale Without Immediate Cash Consideration
Elixinol has also signed a binding agreement to acquire Australian personalised supplement subscription platform Vitable in an all-scrip transaction valued at A$2.5 million of equity, payable in five tranches, plus a performance-based Platform Kicker. The deal remains subject to shareholder approval at a general meeting expected in November.
The proposed combination is targeting more than A$20 million of annual revenue on a pro forma 2026 basis. Elixinol separately says the combined business is targeting A$27 million of revenue and A$3 million of EBITDA by 2028 if the earn-out terms are fully realised. Those are targets rather than reported outcomes, and the transaction will need shareholder backing before the proposed expansion can proceed.
The deal follows the Vitable scrip acquisition, which was announced as adding more than 7,850 active subscribers. Because consideration is in shares rather than cash, the immediate funding burden is limited, but existing shareholders will need to weigh the potential scale benefits against dilution and execution risk.
US Exit Sharpens Australian Focus
Elixinol completed the sale of its US business to Ananda Health on 4 September for headline consideration of approximately A$465,000, comprising A$250,000 upfront and up to A$215,000 in deferred and contingent proceeds. Management said the sale reduces exposure to the changing US regulatory environment and allows the group to concentrate on its Australian portfolio.
The divestment completes the current portfolio reset: a smaller operating base, stronger emphasis on owned brands and greater retail exposure through Priceline and Coles. The next quarter will show whether September’s 18% year-on-year revenue increase marks a sustained acceleration or simply a stronger month within a still uneven recovery.
Bottom Line?
Elixinol’s margin and cost gains are encouraging, but the next proof point is converting adjusted cash generation into durable statutory cash flow while funding the proposed Vitable expansion.
Questions in the middle?
- Can Elixinol sustain positive underlying operating cash flow after divestment-related and other non-recurring costs fall away?
- Will shareholders approve the Vitable transaction, and what level of dilution will the staged equity consideration create?
- Can Priceline, Coles and subscription channels lift revenue quickly enough to offset the group’s limited cash buffer and debt obligations?